IN2014CH00395A - - Google Patents

Info

Publication number
IN2014CH00395A
IN2014CH00395A IN395CH2014A IN2014CH00395A IN 2014CH00395 A IN2014CH00395 A IN 2014CH00395A IN 395CH2014 A IN395CH2014 A IN 395CH2014A IN 2014CH00395 A IN2014CH00395 A IN 2014CH00395A
Authority
IN
India
Prior art keywords
pharmacologically acceptable
cellular immunity
transdermal
antigen
provides
Prior art date
Application number
Other languages
English (en)
Inventor
Yoshiki Maeda
Katsuyuki Okubo
Daisuke Asari
Arimichi Okazaki
takuya Shishido
Kyohei Matsushita
Wenjing Li
Mitsuhiko Hori
Haruo Sugiyama
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of IN2014CH00395A publication Critical patent/IN2014CH00395A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IN395CH2014 2013-02-05 2014-01-29 IN2014CH00395A (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013020731 2013-02-05

Publications (1)

Publication Number Publication Date
IN2014CH00395A true IN2014CH00395A (de) 2015-04-03

Family

ID=50028735

Family Applications (1)

Application Number Title Priority Date Filing Date
IN395CH2014 IN2014CH00395A (de) 2013-02-05 2014-01-29

Country Status (8)

Country Link
US (1) US20140220058A1 (de)
EP (1) EP2762157A1 (de)
JP (1) JP2014169280A (de)
KR (1) KR20140100420A (de)
CN (1) CN103961698A (de)
CA (1) CA2840954A1 (de)
IN (1) IN2014CH00395A (de)
RU (1) RU2014102944A (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071051B2 (en) 2013-02-05 2018-09-11 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
KR20140100419A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 조성물
KR20160058772A (ko) * 2013-10-03 2016-05-25 닛토덴코 가부시키가이샤 점막 백신 조성물
CA2923026A1 (en) * 2013-10-03 2015-04-09 Nitto Denko Corporation Nasal mucosal vaccine composition
MX2016003321A (es) 2013-10-03 2016-08-12 Nitto Denko Corp Composicion de vacuna para mucosa.
CN106714827A (zh) * 2014-10-02 2017-05-24 日东电工株式会社 经皮给药用疫苗药物组合物
EP3281641B1 (de) 2015-04-07 2020-12-16 Cytlimic Inc. Adjuvant für krebsimpfstoffe
EP3527216B1 (de) 2016-10-11 2024-02-14 NEC Corporation Arzneimittel, das einen toll-like-rezeptor-agonist, lag-3-protein, ein derivat des hsp70 peptids und ein derivat des gpc3 peptids
RU2751037C1 (ru) * 2020-04-03 2021-07-07 Богдан Иванович Асатуров Фармацевтическая композиция на основе аутобиокомпонентов мочи человека для трансдермального применения с лечебной или косметической целью

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
JPH069424A (ja) * 1992-04-17 1994-01-18 Takeda Chem Ind Ltd 経粘膜用製剤
CN101002727A (zh) * 1996-11-14 2007-07-25 (由国防部长代表的)美利坚合众国政府 经皮免疫之佐剂
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
JP4422903B2 (ja) 1998-07-31 2010-03-03 株式会社癌免疫研究所 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
AU4188100A (en) * 1999-04-08 2000-11-14 Gregory M. Glenn Dry formulation for transcutaneous immunization
AU2273701A (en) * 1999-12-13 2001-06-18 Epimmune, Inc. Hla class i a2 tumor associated antigen peptides and vaccine compositions
US7709458B2 (en) 2004-03-15 2010-05-04 David K. R. Karaolis Method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
US7622119B2 (en) 2004-03-31 2009-11-24 International Institute Of Cancer Immunology, Inc. Cancer antigen peptides derived from WT1
DE102004049223A1 (de) 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
JP5006196B2 (ja) * 2005-08-01 2012-08-22 久光製薬株式会社 経皮または経粘膜投与のためのアジュバントおよび製剤
EP1988163B1 (de) 2006-02-22 2012-06-27 International Institute of Cancer Immunology, Inc. Hla-a*3303-beschränktes wt1-peptid, und pharmazeutische zusammensetzung, die dieses enthält
US20080112974A1 (en) 2006-09-08 2008-05-15 Duotol Ab Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens
JP2008127277A (ja) * 2006-11-16 2008-06-05 Osaka Prefectural Hospital Organization 免疫賦活化促進剤
EP2980219B1 (de) 2006-12-28 2018-11-14 International Institute of Cancer Immunology, Inc. Hla-a*1101-beschränktes wt1-peptid und pharmazeutische zusammensetzung damit
WO2010013350A1 (ja) * 2008-08-01 2010-02-04 Ａｓｐｉｏｎ株式会社 Ｓ／ｏ型経皮免疫剤
WO2011026111A1 (en) * 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
BR112013032410A2 (pt) * 2011-06-24 2017-01-17 Epitogenesis Inc composições farmacêuticas compreendendo uma combinação de veículos, vitaminas, taninos e flavonoides de seleção como imunomoduladores específicos de antígeno
EP2868325B1 (de) * 2012-07-02 2017-11-01 Sumitomo Dainippon Pharma Co., Ltd. Transdermales krebs-antigen-peptidpräparat
CA2840974A1 (en) * 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for mucosal administration
US20140220056A1 (en) * 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for transdermal administration

Also Published As

Publication number Publication date
EP2762157A1 (de) 2014-08-06
RU2014102944A (ru) 2015-08-10
CA2840954A1 (en) 2014-08-05
JP2014169280A (ja) 2014-09-18
US20140220058A1 (en) 2014-08-07
CN103961698A (zh) 2014-08-06
KR20140100420A (ko) 2014-08-14

Similar Documents

Publication Publication Date Title
IN2014CH00395A (de)
IN2014CH00396A (de)
PH12016500739A1 (en) Inhibitors of the fibrolast growth factor receptor
CR20150647A (es) Sistema de liberación transdérmica
PH12016501122A1 (en) Delayed release compositions of linaclotide
IN2014CH00391A (de)
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
MX2016011862A (es) Inhibidores de c5a para el tratamiento de la neumonia viral.
IN2014CH00393A (de)
TW201144301A (en) Processes for preparing linezolid
EA032927B1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
BR112016014880A2 (pt) Composição farmacêutica incluindo palonosetron
MX2016001138A (es) Compuestos de benzoxaborol triciclico, metodo de preparacion y uso del mismo.
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
IN2013MU01985A (de)
IN2014CH00386A (de)
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
PH12016500847A1 (en) Multi-particulate drug delivery system
IN2014CH00390A (de)
EA201690378A1 (ru) Вакцинные композиции против наркотической зависимости
IN2014KN02584A (de)
IN2013MU02813A (de)
MX2016002186A (es) Proceso para preparar dronedarona y sales de la misma.
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.
UA84282U (ru) Способ медицинской реабилитации больных острыми вирусными гепатитами